National external quality assessment for next-generation sequencing-based diagnostics of primary immunodeficiencies.
Adaptor Proteins, Signal Transducing
/ genetics
Agammaglobulinaemia Tyrosine Kinase
/ genetics
Cytoskeletal Proteins
/ genetics
Genetic Testing
/ methods
High-Throughput Nucleotide Sequencing
/ methods
Humans
Mutation
Netherlands
Primary Immunodeficiency Diseases
/ diagnosis
Quality Assurance, Health Care
Journal
European journal of human genetics : EJHG
ISSN: 1476-5438
Titre abrégé: Eur J Hum Genet
Pays: England
ID NLM: 9302235
Informations de publication
Date de publication:
01 2021
01 2021
Historique:
received:
31
01
2020
accepted:
21
07
2020
revised:
10
06
2020
pubmed:
1
8
2020
medline:
17
8
2021
entrez:
1
8
2020
Statut:
ppublish
Résumé
Dutch genome diagnostic centers (GDC) use next-generation sequencing (NGS)-based diagnostic applications for the diagnosis of primary immunodeficiencies (PIDs). The interpretation of genetic variants in many PIDs is complicated because of the phenotypic and genetic heterogeneity. To analyze uniformity of variant filtering, interpretation, and reporting in NGS-based diagnostics for PID, an external quality assessment was performed. Four main Dutch GDCs participated in the quality assessment. Unannotated variant call format (VCF) files of two PID patient analyses per laboratory were distributed among the four GDCs, analyzed, and interpreted (eight analyses in total). Variants that would be reported to the clinician and/or advised for further investigation were compared between the centers. A survey measuring the experiences of clinical laboratory geneticists was part of the study. Analysis of samples with confirmed diagnoses showed that all centers reported at least the variants classified as likely pathogenic (LP) or pathogenic (P) variants in all samples, except for variants in two genes (PSTPIP1 and BTK). The absence of clinical information complicated correct classification of variants. In this external quality assessment, the final interpretation and conclusions of the genetic analyses were uniform among the four participating genetic centers. Clinical and immunological data provided by a medical specialist are required to be able to draw proper conclusions from genetic data.
Identifiants
pubmed: 32733070
doi: 10.1038/s41431-020-0702-0
pii: 10.1038/s41431-020-0702-0
pmc: PMC7852558
doi:
Substances chimiques
Adaptor Proteins, Signal Transducing
0
Cytoskeletal Proteins
0
PSTPIP1 protein, human
0
Agammaglobulinaemia Tyrosine Kinase
EC 2.7.10.2
BTK protein, human
EC 2.7.10.2
Types de publication
Journal Article
Multicenter Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
20-28Références
Am J Hum Genet. 2007 Apr;80(4):588-604
pubmed: 17357067
EJIFCC. 2018 Apr 30;29(1):4-14
pubmed: 29765282
Hum Mutat. 2019 Dec;40(12):2230-2238
pubmed: 31433103
Clin Microbiol Infect. 2018 Apr;24(4):355-360
pubmed: 29117578
J Clin Immunol. 2018 Jan;38(1):129-143
pubmed: 29226301
J Clin Immunol. 2018 Apr;38(3):320-329
pubmed: 29675737
Eur J Hum Genet. 2019 Feb;27(2):325-330
pubmed: 30291343
J Med Genet. 2016 Sep;53(9):575-90
pubmed: 27250108
Bioinformatics. 2011 Aug 1;27(15):2156-8
pubmed: 21653522
Clin Chem. 2007 Feb;53(2):159-60
pubmed: 17259244
Genome Med. 2019 Jun 17;11(1):38
pubmed: 31203817
Genes Immun. 2006 Mar;7(2):85-94
pubmed: 16395391
Genet Med. 2015 May;17(5):405-24
pubmed: 25741868
J Community Genet. 2010 Mar;1(1):11-7
pubmed: 22422356
Br J Dermatol. 2018 May;178(5):1111-1118
pubmed: 29247509
Hum Mutat. 2013 Oct;34(10):1313-21
pubmed: 23776008
Nat Biotechnol. 2015 Jul;33(7):689-93
pubmed: 26154004
J Clin Immunol. 2018 Jan;38(1):96-128
pubmed: 29226302
J Mol Diagn. 2016 Jul;18(4):572-9
pubmed: 27155050